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Translational Relevance 
In this study we report that talazoparib demonstrates encouraging efficacy in BRCA-mutated 
advanced breast cancer, both in patients whose cancer responded to prior platinum therapy 
(cohort 1) and patients who had received at least three prior nonplatinum cytotoxic 
chemotherapy regimens for advanced disease (cohort 2). Adverse events were primarily mild to 
moderate in severity. In cohort 1, a longer platinum-free interval was associated with increased 
efficacy (defined by objective response rate and progression-free survival) with talazoparib.  
The findings presented in this manuscript are important as they show that a heavily pretreated 
population (who had not received prior platinum) could be highly responsive to talazoparib. 
Additionally, given the increased use of platinum chemotherapy in patients with BRCA-mutated 
advanced breast cancer, this study emphasizes the need to robustly assess the activity of 
PARP inhibitors in patients with prior platinum exposure and the predictive potential of a 
platinum-free interval. 
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Abstract 
Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with 
advanced breast cancer (aBC). 
Experimental Design: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II 
study of talazoparib (1 mg/day) in germline BRCA mutation carriers with a response to 
prior platinum with no progression on or within 8 weeks of the last platinum dose (cohort 
1) or ≥3 platinum-free cytotoxic regimens (cohort 2) for aBC. Primary endpoint was 
confirmed objective response rate (ORR) by independent radiological assessment.  
Results: We enrolled 84 patients (cohort 1, n = 49; cohort 2, n = 35) from May 2014 to 
February 2016. Median age was 50 (range, 31–75) years. Triple-negative breast cancer 
incidence was 59% (cohort 1) and 17% (cohort 2). Median number of prior cytotoxic 
regimens for aBC was two and four, respectively. Confirmed ORR was 21% (95% CI, 
10 to 35) (cohort 1) and 37% (95% CI, 22 to 55) (cohort 2). Median duration of response 
was 5.8 and 3.8 months, respectively. Confirmed ORR was 23% (BRCA1), 33% 
(BRCA2), 26% (TNBC) and 29% (hormone receptor positive). The most common all-
grade adverse events (AEs) included anemia (52%), fatigue (45%), and nausea (42%). 
Talazoparib-related AEs led to drug discontinuation in three (4%) patients. In an 
exploratory analysis, longer platinum-free interval was associated with higher response 
rate in cohort 1 (0% ORR with interval <8 weeks; 47% ORR with interval >6 months). 
Conclusions: Talazoparib exhibited promising antitumor activity in patients with aBC 
and germline BRCA mutation. 
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Introduction 
Breast cancer susceptibility (BRCA) genes 1 and 2 (BRCA1 and BRCA2 [BRCA1/2]) 
are key components in the repair pathway for DNA double-strand breaks. Mutations in 
these genes account for 20% to 25% of hereditary breast cancers and approximately 
5% of all breast cancers (1).  
With improved understanding of the functions of BRCA1/2 in DNA repair, the focus of 
developmental therapeutics has shifted in recent years from cytotoxic chemotherapy to 
molecularly targeted agents. Cancer cells with a BRCA1/2 mutation are deficient in 
homologous recombination DNA repair, and poly(ADP-ribose) polymerase (PARP) 
inhibition causes synthetic lethality in these cells. This is at least in part because PARP 
inhibition traps PARP on sites of DNA damage, creating DNA damage that cannot be 
repaired in cancer cells with defective homologous recombination DNA repair 
mechanisms (2–4). This vulnerability in BRCA-mutant tumors has led to the clinical 
development of PARP inhibitors for a variety of cancers (2–9). Talazoparib is an oral 
PARP inhibitor that has recently emerged as a promising anticancer therapy (5). In 
nonclinical models, talazoparib has been shown to be the most potent PARP inhibitor in 
development, with the lowest concentrations required for inhibition of PARP enzymatic 
activity and PARP trapping at DNA breaks (9–11).   
In the first-in-human phase I study, the maximum tolerated dose of talazoparib was 
defined as 1 mg once daily; the dose-limiting toxicity was reversible thrombocytopenia. 
Talazoparib treatment resulted in a 50% response rate and an 86% clinical benefit rate 
at 24 weeks in 18 patients with a germline BRCA1/2 mutation and advanced breast 
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cancer (5). Treatment-emergent adverse events (AEs) in the phase I trial were 
hematologic and gastrointestinal toxicity.  
The purpose of this phase II study (ABRAZO, NCT02034916) was to evaluate the 
efficacy and safety of talazoparib as a single agent in patients with advanced breast 
cancer with a germline BRCA1/2 mutation. Cohort 1 included patients with platinum-
sensitive disease to explore the impact of previous platinum therapy on the 
effectiveness of subsequent treatment with a PARP inhibitor, as it had been previously 
demonstrated that patients with ovarian cancer treated with other PARP inhibitors who 
had platinum-resistant disease (progression within 6 months after the last dose of 
platinum) or platinum-refractory disease (progression on or within 2 months following 
last dose of platinum) showed a lower observed response rate than patients with longer 
platinum-free intervals (6, 7). Cohort 2 was designed to investigate the response rate in 
a heavily pretreated population who had not received previous platinum therapy.   
 
Methods 
Study design and participants 
This open-label, two-cohort, phase II study evaluated talazoparib in patients with 
metastatic breast cancer with a deleterious or a suspected deleterious germline 
BRCA1/2 mutation using the BRACAnalysis CDx assay (Myriad Genetics, Salt Lake 
City, UT, USA). We enrolled patients from 33 locations throughout France, Germany, 
Spain, the United Kingdom, and the United States. Initially, a total of 35 patients were 
enrolled in stage 1 into each of two cohorts. If five or more patients had objective 
9 
 
responses as determined by the local investigator in either cohort, an additional 
35 patients were to be enrolled in stage 2 into that cohort, for a total of up to 
140 patients in the study. Final assessment of ORR (all patients) was performed by an 
independent central review.  
Cohort 1 included patients with a complete response or partial response to a previous 
platinum-containing regimen for metastatic disease, with no disease progression within 
8 weeks of the last dose of platinum therapy. For patients treated with more than 
one previous platinum-containing regimen, platinum response and stability of disease 
from the last dose had to occur with the most recent regimen. Seven patients in cohort 1 
were enrolled in violation of the eligibility criteria because of disease progression within 
8 weeks of the last dose of platinum. These patients are included in all analyses. 
Cohort 2 included patients who had received three or more previous cytotoxic 
chemotherapy regimens for metastatic disease and no previous platinum therapy for 
metastatic disease. Previous adjuvant or neoadjuvant therapy with platinum was 
allowed if the first disease recurrence was more than 6 months after the last dose of 
adjuvant or neoadjuvant platinum therapy. Patients with human epidermal growth factor 
receptor 2 (HER2)-positive disease were eligible for either cohort, provided they were 
considered to be refractory to HER2-targeted therapy. Patients with HER2-positive breast 
cancer had to have discontinued HER2-directed therapies prior to day 1, although there might 
have been some overlap due to washout. Furthermore, HER2-directed combination therapy was 
not permitted on study.  
In addition to the key eligibility standards described for cohorts 1 and 2 above, 
additional criteria included measurable disease as defined by Response Evaluation 
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Criteria In Solid Tumors version 1.1 (RECIST v 1.1), an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1, and adequate organ and bone marrow 
function. A full list of exclusion criteria is provided in the Supplementary data 
(Supplementary Methods). The study was conducted in accordance with the protocol, 
good clinical practice standards, the Declaration of Helsinki, and the International 
Conference on Harmonisation. The appropriate institutional review board or ethics 
committee at each participating institution approved the protocol. All enrolled patients 
provided written informed consent before undergoing study-specific procedures. 
 
Study treatments and procedures 
Patients received talazoparib 1 mg once daily by mouth as continuous therapy; patients 
were evaluated in repeated 21-day cycles. Talazoparib dosing could be interrupted for 
recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment 
could be resumed at the same or a reduced dose at the discretion of the sponsor and 
investigator if clinical benefit was evident. Patients had study visits on days 1, 8, and 15 
for the first two cycles; the day 8 and 15 visits were optional for subsequent cycles in 
the absence of significant toxicities. Treatment with talazoparib continued until 
radiographic disease progression, unacceptable toxicity, withdrawal of consent, or the 
investigator’s decision to discontinue treatment. End-of-treatment assessments were 
performed 30 days after the last dose of the study drug or before initiation of a new 
antineoplastic therapy, whichever occurred first. 
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An independent radiology facility evaluated imaging data and prior and on-study 
radiation therapy. Tumor assessments were performed by computed tomography, 
magnetic resonance imaging, or radiography. Tumor assessments were performed at 
screening or baseline, every 6 weeks for the first 24 weeks, and every 12 weeks 
thereafter until radiographic disease progression was confirmed by the independent 
radiology facility or until initiation of a new antineoplastic therapy. Tumor response could 
also be assessed as clinically indicated, at the time of clinical suspicion of disease 
progression, and to confirm complete or partial response at least 4 weeks after an initial 
response was observed.  
All patients were monitored for survival and subsequent anticancer therapy every 
60 days after the last dose of study drug for the first year, every 90 days thereafter, and 
at the sponsor’s request. Survival follow-up continued until death or withdrawal of 
consent.   
Safety and tolerability were evaluated by assessment of AEs; physical examinations; 
vital signs; laboratory evaluations; electrocardiograms; and use of concomitant 
medications during the treatment period through 30 days after the last dose of study 
drug or before initiation of a new antineoplastic therapy or investigational therapy, 
whichever occurred first.   
Sparse pharmacokinetic sampling was performed on day 1 of cycles 1 through 4, 
consisting of a predose sample collected no more than 60 minutes prior to dosing and 
two postdose samples collected at least 30 minutes after dosing. The collection times of 
the two postdose samples were separated by at least 2 hours. Blood and tumor tissue 
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samples were collected for pharmacodynamic and genomic research. These analyses 
will be reported separately. 
 
Outcomes 
The intention-to-treat analysis population was defined as all patients with an enrollment 
date (n = 84). The tumor-evaluable population was defined as all patients who had 
received at least one dose of talazoparib, had a baseline tumor assessment, and had at 
least one postbaseline tumor assessment (n = 83). This population was used for the 
efficacy analysis, with the exception of progression-free survival and overall survival, 
which used the intention-to-treat population. 
The primary efficacy endpoint was objective response rate (ORR), defined as the 
proportion of  patients in the tumor-evaluable population who had a confirmed objective 
response (best overall response of complete or partial response) confirmed by the 
independent radiology facility using Response Evaluation Criteria In Solid Tumors 
version 1.1 at the time of data cutoff. Secondary efficacy endpoints were clinical benefit 
rate at 24 weeks and duration of response confirmed by the independent radiology 
facility, progression-free survival confirmed by the investigator, and overall survival. 
Exploratory endpoints were ORR, clinical benefit rate at 24 weeks, and duration of 
response assessed by the investigator. 
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Statistical analysis 
This study was designed to provide adequate power for the primary efficacy endpoint of 
ORR. We initially planned for a total enrollment of up to 140 patients, depending on the 
number of patients with an objective response in the first stage of each cohort using the 
two-stage design. If five or more responses were observed for 35 patients in the first 
stage of each cohort, enrollment of an additional 35 patients into each cohort was to 
occur in the second stage, for a total of 70 treated patients per cohort. Talazoparib 
would be considered effective as a single agent if at least 16 patients in a cohort had an 
objective response. This design provided 0.90 power to distinguish between an active 
drug with a 30% true response rate and a drug with a response rate of 15% or less with 
an alpha level of 0.05. 
After the trial met the criteria for continuation to the second stage for each of the two 
cohorts, the sponsor stopped enrollment in this study, after an amendment to the phase 
III EMBRACA trial (NCT01945775) of talazoparib versus physician’s choice of 
chemotherapy in patients with advanced breast cancer and a germline BRCA1/2 
mutation resulted in overlapping enrollment criteria with this phase II study.  
 
Results 
Patient characteristics 
Between May 2014 and February 2016, we enrolled 84 patients in the intention-to-treat 
population. Patient disposition for the intention-to-treat population is shown in Fig. 1. 
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One patient in cohort 1 did not receive any study drug because of rapidly worsening 
liver function tests and was excluded, for a total of 83 patients in the tumor-evaluable 
population, including 48 patients in cohort 1 and 35 patients in cohort 2. All 83 patients 
were included in the safety population. 
Baseline characteristics of patients are given in Table 1. BRCA1/2 status was assessed 
by a central laboratory for 79 patients; patients had to carry at least one risk factor for 
hereditary breast cancer in order to be screened by the central laboratory for this trial. 
BRCA1/2 status was determined by local assessment for four of the remaining 
five patients whose samples were not available for central assessment, and BRCA1/2 
status was unknown for one patient (the local BRCA1/2 mutation report was not entered 
into the database prior to database lock. There was an insufficient amount of material to 
obtain a result so the patient was listed as unknown. However, the sample was then 
retested by a central laboratory and appeared to be a BRCA mutant). No patient carried 
mutations in both BRCA1 and BRCA2 genes.  
 
Treatment efficacy 
The cutoff date for all efficacy analyses was September 1, 2016 (nine patients 
continued on treatment at this time), with the exception of overall survival for which the 
data cutoff was April 7, 2017. Talazoparib demonstrated efficacy in patients with a 
BRCA1/2 mutation and a response to previous platinum therapy (cohort 1), and in 
patients who had at least three previous chemotherapy regimens and no previous 
platinum therapy (cohort 2; Table 2). In an examination of subgroups in this study, the 
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ORR (95% CI) in patients carrying a BRCA1 or BRCA2 mutation was 23% (11–39) and 
33% (20–50; Fig. 2A, B), and the ORR (95% CI) in patients with triple-negative breast 
cancer (TNBC) and hormone receptor–positive breast cancer was 26% (13–43) and 
29% (17–44; Fig. 2C, D). The study recruited six patients with HER2-positive breast 
cancer, who were considered refractory to previous HER2-targeting therapies. All 
HER2-positive breast cancers were also hormone receptor positive. In these patients, 
an objective response was confirmed in two of the six patients by the independent 
radiology facility.     
Investigator-assessed median progression-free survival was 4.0 months (95% CI, 2.8–
5.4) in cohort 1 and 5.6 months (95% CI, 5.5–7.8) in cohort 2 (Supplementary Fig. S1). 
Based on reverse Kaplan–Meier estimates, the median follow-up time was 13.7 months 
for each cohort. The median overall survival was 12.7 months (95% CI, 9.6–15.8) in 
cohort 1 and 14.7 months (95% CI, 11.0–24.4) in cohort 2 (Supplementary Fig. S1), with 
36 events (74%) in cohort 1 and 22 events (62.9%) in cohort 2.  
The median time from the last platinum dose to progression in cohort 1 was 4.0 months 
(range, 0.03–49.15). Exploratory subgroup analyses of the effect of platinum-free 
interval on ORR and the median progression-free survival suggested that a longer 
platinum-free interval following the last dose of platinum was associated with greater 
clinical activity (Fig. 3). Of the seven patients who entered cohort 1 with disease 
progression within 8 weeks of the last dose of platinum, none responded to talazoparib. 
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Treatment safety 
Drug-related AEs that led to study drug discontinuation occurred in three patients 
overall, two patients in cohort 1 and one patient in cohort 2, and included anemia (one 
patient) and liver function test abnormalities (two patients). The most common reason 
for dose reduction was myelosuppression (anemia); 23 patients (28%) received at least 
one transfusion of red blood cells. The transfusion rate was higher in cohort 2 (37%), 
the group who had received more prior cytotoxic chemotherapy; 21% of patients in 
cohort 1 received at least one red blood cell transfusion. Few patients received an 
erythropoietin-stimulating agent (8% and 3% for cohorts 1 and 2, respectively). Time to 
first dose reduction was 10.9 weeks in cohort 1 and 13.3 weeks in cohort 2. 
Hematologic treatment-emergent AEs and grade 3 or higher hematologic treatment-
emergent AEs occurring in 15% or more and in 5% or more of patients, respectively, are 
shown in Table 3. In both cohorts, anemia was the most common hematologic AE (50% 
and 57% of patients in cohorts 1 and 2, respectively). Neutropenic sepsis occurred in 
one patient. No acute myeloid leukemia or myelodysplastic syndrome was observed. 
Nonhematologic treatment-emergent AEs and grade 3 or higher nonhematologic 
treatment-emergent AEs occurring in 20% or more and 5% or more of patients, 
respectively, are shown in Table 3. No grade 5 treatment-emergent AEs were observed. 
No clinically significant cardiovascular toxicity was observed.  
 
Pharmacokinetics 
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The plasma concentration of talazoparib at approximately 2 hours following the first 
dose was 3650 pg/mL (coefficient of variation [CV%] 93.6). On cycle 2 day 1 
(approximately 21 days later), the plasma concentration was 10,700 pg/mL (CV% 46.2) 
in patients without a dose modification. Talazoparib plasma trough concentrations were 
similar for cycles 2, 3, and 4 for patients without any dose modification (between 3300 
and 3900 pg/mL), suggesting that talazoparib reached steady state by cycle 2. In 
general, trough concentrations had high interpatient variability, between 46% and 60% 
for patients without dose modification, which was consistent with previous observations 
(5). Talazoparib showed accumulation at steady state where postdose concentrations 
(two postdose samples, >2 hours between) in cycles 2 to 4 were 2.7- to 3-fold higher 
than observed in cycle 1, consistent with historical data. 
 
Discussion 
In this open-label, phase II study of patients with metastatic breast cancer carrying a 
germline BRCA1/2 mutation, talazoparib had clinical activity both in patients who had a 
previous response to platinum chemotherapy and in those who received at least three 
previous cytotoxic regimens for advanced breast cancer without prior platinum 
exposure. In the group who previously received platinum, an exploratory analysis 
demonstrated an association between higher ORR and longer median progression-free 
survival with a longer platinum-free interval.   
Platinum chemotherapy and PARP inhibitors target defective HR DNA repair in 
BRCA1/2-mutant breast cancer. Although the mechanisms of resistance to platinum 
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chemotherapy in this setting are incompletely understood, reversion mutations that 
restore HR repair proficiency appear to play a role in at least some patients. Such 
mutations have been identified in preclinical models and in the circulating tumor DNA of 
heavily pretreated breast cancers (12, 13). In an exploratory analysis, response to 
talazoparib was less likely in patients progressing with a short platinum-free interval 
than in patients with a long platinum-free interval (Fig. 3), suggesting that patients who 
progress on platinum chemotherapy or shortly after stopping may show reduced 
sensitivity to PARP inhibitors. Previous studies of PARP inhibitors in breast cancer have 
included relatively few patients with prior platinum chemotherapy. In a phase II study 
with olaparib, the ORR was 9.5% in 42 patients who had received platinum and was 
20% in 20 patients without prior platinum exposure (14). In the OlympiAD phase III 
study of olaparib, prior platinum chemotherapy as a whole did not affect the relative 
benefit of olaparib (hazard ratio for PFS was 0.67 and 0.60 for patients with and without 
prior platinum), although olaparib efficacy in relation to the timing of platinum 
chemotherapy was not reported (15). Our results emphasize the importance of robustly 
assessing platinum-free interval in future studies. 
The safety profile of PARP inhibitors is generally consistent across the different agents, 
with the primary toxicity being clinically manageable myelosuppression. Additional 
toxicities include mild-to-moderate gastrointestinal toxicity (ie, nausea, vomiting, 
diarrhea, and abdominal pain) and fatigue (16). Three of the 83 evaluable patients from 
our study discontinued therapy for a drug-related toxicity, suggesting that most toxicity 
could be managed with supportive care. Although myelosuppression was common, the 
clinical sequelae (ie, hemorrhage and infection) were rare and included one patient with 
19 
 
a severe but transient episode of epistaxis and one with neutropenic sepsis successfully 
treated for infection and later had a confirmed partial response. Grade 3/4 
thrombocytopenia occurred in 29% (14/48) of patients in cohort 1 and 23% (8/35) of 
patients in cohort 2. Hemorrhage was rare, occurring in only one patient, suggesting 
that thrombocytopenia only rarely had clinical sequelae. No acute myeloid leukemia or 
myelodysplastic syndrome was noted during the median follow up time of 13.7 months. 
Acute myeloid leukemia or myelodysplastic syndrome has been noted to occur at an 
incidence of 1% to 3% among patients following a few months up to several years of 
treatment with PARP inhibitors (3, 17–19), although this has been exclusively reported 
in patients with ovarian cancer. 
There are several limitations to our study. The open-label design may have led to 
investigator bias in assessment of response and progression; therefore, the primary 
endpoint was ORR by independent imaging facility assessment. Additionally, the 
termination of enrollment prior to completion of the targeted 70 patients per cohort limits 
the conclusions that may be drawn from this study. We recruited few patients with 
HER2-positive breast cancer. Although antitumor activity was observed in these 
patients, the data are preliminary and further studies would be required to assess the 
activity of talazoparib in patients with HER2-positive disease. In addition, the two 
cohorts differed in tumor subtype, which may have had an influence on PFS and overall 
survival (Table 1), with triple-negative cancers in general having adverse PFS and 
overall survival compared with estrogen receptor–positive cancers. Of note, a phase III 
clinical trial (EMBRACA, NCT01945775) recently reported improved PFS for talazoparib 
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compared to treatment of physician’s choice, with a doubling of ORR and prolonged 
duration of response (20).  
In conclusion, talazoparib is a novel and highly potent PARP inhibitor with a 
manageable safety profile, pharmacokinetics that support once-daily dosing, and 
encouraging single-agent efficacy in germline BRCA1/2 mutation carriers with advanced 
breast cancer previously treated with platinum and in patients treated with multiple lines 
of prior nonplatinum-based chemotherapy. The impact of prior platinum exposure and 
platinum-free interval on sensitivity to PARP inhibitors should be further investigated. 
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Table 1. Select baseline characteristics (intention-to-treat population) 
Characteristic Cohort 1 
prior platinum therapy  
(n = 49) 
Cohort 2 
third-line treatment, No. 
prior platinum therapy  
(n = 35) 
Total 
(N = 84) 
Age, median (range), years 50 (31 to 74) 52 (33 to 75) 50 (31 to 75) 
ECOG performance status = 0, No. (%) 34 (69) 15 (43) 49 (58) 
History of central nervous system metastasis, No. (%)  8 (16) 1 (3) 9 (11) 
Visceral disease, No. (%) 38 (78) 23 (66) 61 (73) 
Hormone receptor status, No. (%)     
HER2 positive 1 (2) 5 (14) 6 (7) 
Triple negative 29 (59) 6 (17) 35 (42) 
ER positive or PgR positive 20 (41) 29 (83) 49 (58) 
BRCA mutation status, No. (%)    
    BRCA1 positive 26 (53) 15 (43) 41 (49) 
    BRCA2 positive 22 (45) 20 (57) 42 (50) 
    Unknown 1 (2) 0 1 (1) 
Number of prior cytotoxic regimens for advanced disease 
1 to 2, No. (%) 26 (53) 1 (3)* 27 (32) 
3 to 4, No. (%) 17 (35) 22 (63) 39 (46) 
≥5, No. (%) 6 (12) 12 (34) 18 (21) 
Median 2 4 3 
Min, max 1, 10 1, 9 1, 10 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, 
progesterone receptor. *Protocol deviation: eligibility criteria not met (≥3 prior cytotoxic regimens).  
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Table 2. Primary, secondary, and exploratory efficacy endpoints 
Endpoint Cohort 1 
prior platinum therapy 
(n = 48) 
Cohort 2 
Third-line treatment, No. prior 
platinum therapy 
(n = 35) 
Total 
(N = 83) 
Primary efficacy endpoint, objective response rate assessed by independent radiology facility  
Objective response rate, % (95% CI) 21 (10 to 35) 37 (22 to 55) 28 (18 to 39) 
Best overall response, No. (%)    
Complete response 2 (4) 0 2 (2) 
Partial response  8 (17) 13 (37) 21 (25) 
Stable disease 18 (38) 18 (51) 36 (43) 
Progressive disease 18 (38) 4 (11) 22 (27) 
Not evaluable 2 (4) 0 2 (2) 
Secondary efficacy endpoints (intention-to-treat population) 
Duration of response assessed by independent 
radiology facility  
   
No. 10 13 23 
Events, No. (%)  5 (50) 10 (77) 15 (65) 
Median (95% CI), months 5.8 (2.8–NE) 3.8 (2.8–10.1) 4.9 (2.9–9.7) 
Clinical benefit rate assessed by independent 
radiology facility (complete response, partial 
response, or stable disease ≥ 24 weeks), No. (%) 
13 (27) 16 (46) 29 (35) 
95% CI 15–42 29–63 25–46 
Exploratory endpoint, investigator assessments of 
efficacy (tumor-evaluable population) 
Cohort 1 
prior platinum therapy 
(n = 48) 
Cohort 2 
third-line treatment, No. prior 
platinum therapy 
(n = 35) 
Total 
(N = 83) 
Objective response rate, % (95% CI) 23 (12–37) 51 (34–69) 35 (25–46) 
Duration of response    
No. 11 18 29 
Events, No. (%) 8 (73) 15 (83) 23 (79) 
Median (95% CI), months 4.9 (2.8–NE) 4.2 (3.2–5.5) 4.4 (3.2–5.6) 
Clinical benefit rate assessed by investigator 18 (38) 23 (66) 41 (49) 
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(complete response, partial response, or stable 
disease ≥ 24 weeks), No. (%)  
95% CI 24–53 48–81 38–61 
Abbreviations: CI, confidence interval; NE, not evaluable. Confirmation of complete response and partial response required; data cutoff for primary 
endpoint was September 1, 2016. 
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Table 3. Treatment-emergent adverse events in descending order of all grades in cohort 1 (safety population) 
 Cohort 1 
prior platinum therapy 
(n = 48), No. (%) 
Cohort 2 
third-line treatment, No. prior platinum 
therapy 
(n = 35), No. (%) 
 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 
Hematologic* 
Patients with treatment-emergent adverse 
event(s) 
33 (69) 25 (52) 3 (6) 26 (74) 17 (49) 4 (11) 
Anemia 24 (50) 16 (33) 0 20 (57) 14 (40) 0 
Thrombocytopenia 23 (48) 11 (23) 3 (6) 12 (34) 4 (11) 4 (11) 
Neutropenia 15 (31) 6 (13) 0 16 (46) 8 (23) 0 
Leukopenia 10 (21) 1 (2) 0 10 (29) 3 (9) 0 
Nonhematologic
†
 
Patients with treatment-emergent adverse 
event(s) 
47 (98) 11 (23) 2 (4) 34 (97) 10 (29) 1 (3) 
Fatigue 29 (60) 3 (6) 0 8 (23) 0 0 
Nausea 20 (42) 2 (4) 0 15 (43) 0 0 
Diarrhea 17 (35) 1 (2) 0 10 (29) 0 0 
Decreased appetite 11 (23) 1 (2) 0 9 (26) 0 0 
Dyspnea 11 (23) 1 (2) 1 (2) 9 (26) 2 (6) 0 
Alopecia (grade 1) 11 (23) 0 0 7 (20) 0 0 
Back pain 11 (23) 0 0 7 (20) 0 0 
Vomiting 10 (21) 0 0 7 (20) 0 0 
Pleural effusion 4 (8) 3 (6) 0 4 (11) 2 (6) 0 
The category of thrombocytopenia incudes reports of thrombocytopenia and platelet count decreased. The category of neutropenia includes 
reports of neutropenia, decreased neutrophil count, and neutropenic sepsis. The category of anemia includes reports of anemia and hemoglobin 
decreased. *All treatment-emergent adverse events in ≥ 15% of patients and grade 3 and 4 treatment-emergent adverse events in ≥ 5% of 
patients. Transfusions: one patient with platelet transfusion and 23 patients (28%) with packed red blood cells (10 and 13 patients in cohorts 1 and 
2, respectively). Hemorrhage: one patient had grade 3 hemorrhage (transient epistaxis). No patients had acute myeloid leukemia or 
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myelodysplastic syndrome. 
†
All treatment-emergent adverse events in ≥ 20% of patients and grade ≥ 3 treatment-emergent adverse events in ≥ 
5% of patients. No grade 5 treatment-emergent adverse events and no clinically significant cardiovascular toxicities were observed.
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Figure 1. Patient disposition. aIntention-to-treat (ITT) population. 
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Figure 2. Change in tumor size on talazoparib by BRCA mutation status and breast 
cancer subtype. Percentage change by BRCA mutation status in (A) cohort 1 and (B) 
cohort 2 and by breast cancer subtype in (C) cohort 1 and (D) cohort 2. aOngoing 
patients as of data cutoff of September 1, 2016. Line at -30% indicates a partial 
response as determined by RESIST version 1.1. Triple-negative defined as ER-
negative, PgR-negative, and HER2-negative. Hormone receptor–positive, defined as 
ER-positive or PgR-positive, includes 6 patients who were hormone receptor-positive 
and HER2-positive. BRCA, breast cancer susceptibility gene; ER, estrogen receptor; 
HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; 
RESIST, Response Evaluation Criteria In Solid Tumors. 
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Figure 3. Impact of platinum-free interval on efficacy of talazoparib. Exploratory 
assessment of the platinum-free interval (time from last dose of platinum chemotherapy 
to disease progression) and confirmed objective response rate by (A) independent 
review and (B) PFS in cohort 1. ORR, objective response rate; PFS, progression-free 
survival. 
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